154 related articles for article (PubMed ID: 34157485)
1. DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations.
Yang M; Fan Y; Wu ZY; Gu J; Feng Z; Zhang Q; Han S; Zhang Z; Li X; Hsueh YC; Ni Y; Li X; Li J; Hu M; Li W; Gao H; Yang C; Zhang C; Zhang L; Zhu T; Cheng M; Ji F; Xu J; Cui H; Tan G; Zhang MQ; Liang C; Liu Z; Song YQ; Niu G; Wang K
EBioMedicine; 2021 Jul; 69():103446. PubMed ID: 34157485
[TBL] [Abstract][Full Text] [Related]
2. Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
Melhem-Bertrandt A; Bojadzieva J; Ready KJ; Obeid E; Liu DD; Gutierrez-Barrera AM; Litton JK; Olopade OI; Hortobagyi GN; Strong LC; Arun BK
Cancer; 2012 Feb; 118(4):908-13. PubMed ID: 21761402
[TBL] [Abstract][Full Text] [Related]
3. Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores.
Evans DG; Woodward ER; Howell SJ; Verhoef S; Howell A; Lalloo F
Fam Cancer; 2017 Apr; 16(2):173-179. PubMed ID: 27796713
[TBL] [Abstract][Full Text] [Related]
4. Real-world multi-country study of
Lux MP; Lewis K; Rider A; Niyazov A
Future Oncol; 2022 Mar; 18(9):1089-1101. PubMed ID: 35098723
[TBL] [Abstract][Full Text] [Related]
5. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing.
Lang GT; Shi JX; Hu X; Zhang CH; Shan L; Song CG; Zhuang ZG; Cao AY; Ling H; Yu KD; Li S; Sun MH; Zhou XY; Huang W; Shao ZM
Int J Cancer; 2017 Jul; 141(1):129-142. PubMed ID: 28294317
[TBL] [Abstract][Full Text] [Related]
6. Germline and Somatic
Wang X; Kallionpää RA; Gonzales PR; Chitale DA; Tousignant RN; Crowley JP; Chen Z; Yoder SJ; Blakeley JO; Acosta MT; Korf BR; Messiaen LM; Tainsky MA
Cancer Prev Res (Phila); 2018 Oct; 11(10):655-664. PubMed ID: 30104415
[No Abstract] [Full Text] [Related]
7. Prevalence of germline TP53 mutations in HER2+ breast cancer patients.
Rath MG; Masciari S; Gelman R; Miron A; Miron P; Foley K; Richardson AL; Krop IE; Verselis SJ; Dillon DA; Garber JE
Breast Cancer Res Treat; 2013 May; 139(1):193-8. PubMed ID: 23580068
[TBL] [Abstract][Full Text] [Related]
8. [Application of next-generation sequencing in detection of BRCA1/2 and homologous recombination repair pathway multi-genes germline mutation and correlation analysis].
Chen YL; Zhuo ZL; Liu C; Xie F; Yang ZY; Liu PF; Wang S; Zhao XT
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Mar; 56(3):302-311. PubMed ID: 35381651
[No Abstract] [Full Text] [Related]
9. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.
Carraro DM; Koike Folgueira MA; Garcia Lisboa BC; Ribeiro Olivieri EH; Vitorino Krepischi AC; de Carvalho AF; de Carvalho Mota LD; Puga RD; do Socorro Maciel M; Michelli RA; de Lyra EC; Grosso SH; Soares FA; Achatz MI; Brentani H; Moreira-Filho CA; Brentani MM
PLoS One; 2013; 8(3):e57581. PubMed ID: 23469205
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.
Zhang J; Pei R; Pang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Breast Cancer Res Treat; 2012 Apr; 132(2):421-8. PubMed ID: 21614564
[TBL] [Abstract][Full Text] [Related]
11. Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.
Han BY; Chen C; Luo H; Lin CJ; Han XC; Nasir J; Shi JX; Huang W; Shao ZM; Ling H; Hu X
Cancer Lett; 2024 Apr; 588():216763. PubMed ID: 38403109
[TBL] [Abstract][Full Text] [Related]
12. Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort.
Akter H; Sultana N; Martuza N; Siddiqua A; Dity NJ; Rahaman MA; Samara B; Sayeed A; Basiruzzaman M; Rahman MM; Rashidul Hoq M; Amin MR; Baqui MA; Woodbury-Smith M; Uddin KMF; Islam SS; Awwal R; Berdiev BK; Uddin M
BMC Med Genet; 2019 Sep; 20(1):150. PubMed ID: 31477031
[TBL] [Abstract][Full Text] [Related]
13. HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers.
Wang T; Xu Y; Sheng S; Yuan H; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Cancer Sci; 2017 Apr; 108(4):671-677. PubMed ID: 28164408
[TBL] [Abstract][Full Text] [Related]
14. Detection of novel germline mutations for breast cancer in non-BRCA1/2 families.
Aloraifi F; McDevitt T; Martiniano R; McGreevy J; McLaughlin R; Egan CM; Cody N; Meany M; Kenny E; Green AJ; Bradley DG; Geraghty JG; Bracken AP
FEBS J; 2015 Sep; 282(17):3424-37. PubMed ID: 26094658
[TBL] [Abstract][Full Text] [Related]
15. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations.
Wilson JR; Bateman AC; Hanson H; An Q; Evans G; Rahman N; Jones JL; Eccles DM
J Med Genet; 2010 Nov; 47(11):771-4. PubMed ID: 20805372
[TBL] [Abstract][Full Text] [Related]
16. The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer.
Chen L; Fu F; Huang M; Lv J; Zhang W; Wang C
Breast Cancer Res Treat; 2020 Apr; 180(3):759-766. PubMed ID: 32072338
[TBL] [Abstract][Full Text] [Related]
17. Association between HER2 germline mutation A270S and prognosis in patients with primary breast cancer.
Si P; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Cancer Biomark; 2018; 23(2):165-171. PubMed ID: 30175972
[TBL] [Abstract][Full Text] [Related]
18. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
19. Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
Fan Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
Breast Cancer Res Treat; 2018 May; 169(1):59-67. PubMed ID: 29356917
[TBL] [Abstract][Full Text] [Related]
20. Genetic testing in a cohort of young patients with HER2-amplified breast cancer.
Eccles DM; Li N; Handwerker R; Maishman T; Copson ER; Durcan LT; Gerty SM; Jones L; Evans DG; Haywood L; Campbell I
Ann Oncol; 2016 Mar; 27(3):467-73. PubMed ID: 26681682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
